Nora Pratt

Nora Pratt is the last set of eyes on everything published here. Her job is to check that every claim traces back to a real source, that study findings aren't stretched past what they support, and that no article implies a treatment recommendation. She came from long-form editorial work in consumer health, where she built the habit of asking "compared to what, and in how many people?" of every sentence. She also writes our pricing and industry coverage, which turns out to be the same job in a different form. A company announcing a fifty percent price cut is making a claim, and the useful question is the one she asks of everything else: compared to what, for whom, and does the number survive contact with what people actually pay. She doesn't write clinical content and doesn't give advice — she makes sure the people who do stay accurate. She's also the reason this site's articles say "may" more often than most.

Medicaid coverage of Wegovy and Zepbound added fewer prescriptions than it appeared

by
Medicaid coverage of Wegovy and Zepbound added fewer prescriptions than it appeared

When a state Medicaid programme starts paying for GLP-1 drugs labeled for obesity, the bill for those drugs goes up. A study in JAMA Health Forum suggests the net increase is smaller than that figure implies, because some of the new obesity-labeled prescriptions appear to replace diabetes-labeled versions of the same molecules, which every state … Read more

26 economic studies on weight-loss drugs, and what ‘cost-effective’ leaves out

by
Typographic title card: review of 26 economic evaluations of weight-loss drugs

A systematic review has pulled together 26 economic evaluations of the approved weight-loss drugs, and the pattern it reports is worth knowing before anyone quotes “cost-effective” at you. Semaglutide came out ahead of liraglutide consistently enough that the authors call liraglutide generally not cost-effective. Tirzepatide bought the most health of any drug reviewed, and frequently … Read more

Route of administration outranked weight loss in an 800-person preference survey

by
Route of administration outranked weight loss in an 800-person preference survey

Asked to choose between hypothetical weight-loss drugs, 800 American adults ranked how a drug is taken above how much weight it takes off. In a discrete-choice survey published on 17 September, route of administration was the single most important attribute driving choice, ahead of average weight loss, cardiovascular risk reduction and the share of people … Read more

Lilly-authored analysis says Zepbound offsets other healthcare costs after 55

by
Does Zepbound offset other healthcare costs after 55?

Eli Lilly announced on 26 August 2026 that a real-world analysis of adults over 55 found lower healthcare costs among people who stayed on Zepbound (tirzepatide) than among matched untreated adults, and framed the result against the $195 monthly net price under Medicare’s GLP-1 Bridge programme. The underlying paper is peer-reviewed and published in Diabetes, … Read more